Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. reports developments across its biotechnology medicines business, including discovery, development, manufacturing and delivery of human therapeutics. Company updates center on a portfolio and pipeline spanning cancer, inflammatory conditions, rare diseases, heart disease, obesity and obesity-related conditions, with named products and programs such as TEPEZZA, Repatha and IMDELLTRA appearing in clinical and commercial announcements.
Recurring news also covers quarterly financial results, non-GAAP performance measures, manufacturing network investments, supply-chain capacity, research collaborations, medical and investor conference presentations, and executive or organizational changes tied to the integration of biology, technology, artificial intelligence and data across Amgen's operations.
Amgen (NASDAQ: AMGN) reported Q4 2025 and full-year results on Feb 3, 2026. Total revenues rose 10% year-over-year to $36.8 billion for 2025; product sales increased 10% to $35.15 billion. GAAP EPS was $14.23 for FY 2025 (up 88%); free cash flow was $8.1 billion. The company recorded a $1.2 billion Otezla intangible-asset impairment and reported mixed product performance, including strong growth for Repatha, TEZSPIRE and UPLIZNA and significant declines for Enbrel and other legacy products.
Amgen (NASDAQ:AMGN) will report fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after U.S. market close. A conference call with management will follow at 4:30 p.m. ET, and live audio webcast will be available on Amgen's Investor Relations site.
The webcast will be archived and available for replay for at least 90 days on the company's website.
Summary not available.
Amgen (NASDAQ:AMGN) will present at the 2026 J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Monday, January 12, 2026. Robert A. Bradway, chairman and chief executive officer, will deliver the presentation. The event will be webcast live and available to media, investors and the public via Amgen's website under Investors. Presentation times and webcast links are listed on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
Amgen (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics for up to $840 million on Jan 6, 2026. The deal brings DBT 3757, a MLLT1/3-targeted investigational degrader currently in IND-enabling studies, into Amgen's oncology portfolio for development in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Amgen plans to integrate Dark Blue into its research organization to accelerate clinical advancement. Investors backing Dark Blue included Oxford Science Enterprises, Bristol Myers Squibb, and Evotec; BofA served as financial advisor.
Amgen (NASDAQ: AMGN) announced on Jan 6, 2026 the acquisition of Dark Blue Therapeutics for up to $840 million. The deal adds an investigational small molecule that targets and degrades proteins MLLT1/3, aimed at specific types of acute myeloid leukemia (AML).
Preclinical leukemia models showed promising anti-cancer activity and a mechanism differentiated from current therapies, supporting potential single-agent and combination use to address treatment resistance and durability of remission. Amgen said it will integrate Dark Blue into its research organization to strengthen early oncology discovery and advance the program toward clinical investigation.
Amgen (NASDAQ:AMGN) said it is taking action with the U.S. government to lower medicine costs for American patients while reaffirming investment in U.S. innovation and manufacturing.
Key moves: AmgenNow™ will add Aimovig and Amjevita at a discounted monthly price of $299 (about 60% and 80% below current U.S. list prices); Repatha was made available in October 2025 at $239 monthly. Amgen reported > $40 billion invested in U.S. manufacturing and R&D since 2018 and announced an additional $2.5 billion in U.S. manufacturing investments in 2025, including $900 million in Ohio and $1 billion in North Carolina. Amgen will receive industry tariff relief for the next three years.
Amgen (NASDAQ:AMGN) announced FDA approval of UPLIZNA (inebilizumab-cdon) on December 11, 2025 for treatment of adults with generalized myasthenia gravis (gMG) who are anti-AChR and anti-MuSK antibody positive.
Approval is supported by the Phase 3 MINT trial showing durable symptom control (MG-ADL difference at Week 26: -4.2 vs -2.2, 1.9-point treatment effect; AChR+ exploratory Week 52 difference: 2.8 points). UPLIZNA is the first CD19-targeted B cell therapy approved for these gMG subtypes, dosed twice yearly after two loading doses. Most common adverse reactions were headache and infusion-related reactions. UPLIZNA is Amgen's third indication after June 2020 and April 2025 approvals.
Amgen (NASDAQ:AMGN) announced a $2.52 per share dividend for Q1 2026. The Board declared the dividend on Dec 9, 2025, with a record date of February 13, 2026 and a payment date of March 6, 2026.
This dividend applies to all stockholders of record as of the close of business on the record date.
Amgen (NASDAQ:AMGN) will present at Citi's 2025 Global Healthcare Conference on December 3, 2025 at 1:45 p.m. ET.
Presenters are Peter Griffith, executive vice president and chief financial officer, and Jay Bradner, executive vice president of Research and Development. The presentation will be webcast live and available to media, investors and the public on Amgen's investor website, with the webcast archived for replay for at least 90 days.